Efficacy of Information System Regarding the Consumption of Antibiotics and Bacterial Resistance in Primary Care

Chronic Disease Clinical Trial

— SICAR-Amb  

Official title:

Efficacy of Information System Regarding the Consumption of Antibiotics and Bacterial Resistance on the Use of Antibiotics in Primary Care

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02816528
• Other study ID #: PREPS-15-000171
• Status: Enrolling by invitation
• Start date: June 24, 2016
• Est. completion date: November 2020

Study information

• Verified date: May 2019
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

France is a country strong consumer of antibiotics in Europe, specially in primary care.

Outpatient antibiotic use represents around 90% of total antibiotic use and prescriptions come mainly from general practitioners. A literature review of antibiotic stewardship in primary care show that there is no evaluation of interest of giving information about consumption of antibiotics and bacterial resistance to general practitioners. The objective of this study is to demonstrate that practitioners implicated in the followed of consumption of antibiotics and bacterial resistance around their geographical area of practice could change and improve their practices in good use of antibiotics.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 472
• Est. completion date: November 2020
• Est. primary completion date: June 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• General practitioners in a "Meurthe-et-Moselle" french department

Exclusion Criteria:

• General practitioners out of "Meurthe-et-Moselle" french department

Related Conditions & MeSH terms

• Chronic Disease

Intervention

Behavioral:
• Training program
Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France	CNAMTS, Caisse Nationale d’Assurance Maladie des Travailleurs salariés, France, Direction Générale de l'Offre de Soins, MedQual, Nantes, France

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Consumption of antibiotics	Antibiotics consumptions are provided by CNAMTS and calculated in defined daily dose DDD/1000 patient-days around the geographical area concerned by this study.	36 months
Secondary	Bacterial resistance of Escherichia coli and Staphylococcus aureus	The number of intermediate and resistant strains of E.coli and S.aureus are provided by MedQual around the geographical area concerned by this study.	36 months